Literature DB >> 9614078

Interplay of the proto-oncogene proteins CrkL and CrkII in insulin-like growth factor-I receptor-mediated signal transduction.

A P Koval1, M Karas, Y Zick, D LeRoith.   

Abstract

The closely related proto-oncogene proteins CrkII and CrkL consist of one SH2 and two SH3 domains and share 60% overall homology with the highest identity within their functional domains. In this study we show that CrkL and CrkII may play overlapping but different roles in insulin-like growth factor (IGF)-I receptor-mediated signal transduction. While both proteins are substrates involved in IGF-I receptor signaling, they apparently demonstrate important different properties and different biological responses. Evidence supporting this hypothesis includes (a) the oncogenic potential of CrkL versus the absence of this potential in CrkII overexpressing cell lines, (b) the inhibition of IGF-I-dependent cell cycle progression by overexpression of CrkII, and (c) the differential regulation of the phosphorylation status of selective proteins in CrkII and CrkL overexpressing cell lines. In addition we demonstrate the specific association of CrkL and CrkII with the newly characterized IRS-4 protein, again in a differential manner. Whereas CrkL strongly interacts with IRS-4 via its SH2 and N-terminal SH3 domains, CrkII interacts only via its SH2 domain, possibly explaining the unstable nature of IRS-4-CrkII association. The results obtained allow us to propose a unique mechanism of CrkL and CrkII tyrosine phosphorylation in response to IGF-I stimulation. Thus these highly homologous proteins apparently possess structural features that allow for the differential association of each protein with different effector molecules, thereby activating different signaling pathways and resulting in unique biological roles of these proteins.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9614078     DOI: 10.1074/jbc.273.24.14780

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  8 in total

Review 1.  IGF-I receptor, cell-cell adhesion, tumour development and progression.

Authors:  Loredana Mauro; Eva Surmacz
Journal:  J Mol Histol       Date:  2004-03       Impact factor: 2.611

2.  Differential phosphoproteomics of fibroblast growth factor signaling: identification of Src family kinase-mediated phosphorylation events.

Authors:  Debbie L Cunningham; Steve M M Sweet; Helen J Cooper; John K Heath
Journal:  J Proteome Res       Date:  2010-05-07       Impact factor: 4.466

3.  Escherichia coli virulence protein NleH1 interaction with the v-Crk sarcoma virus CT10 oncogene-like protein (CRKL) governs NleH1 inhibition of the ribosomal protein S3 (RPS3)/nuclear factor κB (NF-κB) pathway.

Authors:  Thanh H Pham; Xiaofei Gao; Gyanendra Singh; Philip R Hardwidge
Journal:  J Biol Chem       Date:  2013-10-21       Impact factor: 5.157

4.  Molecular basis of signaling specificity of insulin and IGF receptors: neglected corners and recent advances.

Authors:  Kenneth Siddle
Journal:  Front Endocrinol (Lausanne)       Date:  2012-02-28       Impact factor: 5.555

5.  Crk-like adapter protein is overexpressed in cervical carcinoma, facilitates proliferation, invasion and chemoresistance, and regulates Src and Akt signaling.

Authors:  Hong Ji; Bo Li; Shitai Zhang; Zheng He; Yang Zhou; Ling Ouyang
Journal:  Oncol Lett       Date:  2016-09-21       Impact factor: 2.967

6.  Phosphorylation of IRS4 by CK1γ2 promotes its degradation by CHIP through the ubiquitin/lysosome pathway.

Authors:  Xinchun Li; Li Zhong; Zhuo Wang; Huiming Chen; Dan Liao; Ruhua Zhang; Hongyu Zhang; Tiebang Kang
Journal:  Theranostics       Date:  2018-06-07       Impact factor: 11.556

Review 7.  The Role of Insulin Receptor Isoforms in Diabetes and Its Metabolic and Vascular Complications.

Authors:  O Escribano; N Beneit; C Rubio-Longás; A R López-Pastor; A Gómez-Hernández
Journal:  J Diabetes Res       Date:  2017-10-19       Impact factor: 4.011

8.  Loss-of-function screen in rhabdomyosarcoma identifies CRKL-YES as a critical signal for tumor growth.

Authors:  C L Yeung; V N Ngo; P J Grohar; F I Arnaldez; A Asante; X Wan; J Khan; S M Hewitt; C Khanna; L M Staudt; L J Helman
Journal:  Oncogene       Date:  2013-01-14       Impact factor: 9.867

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.